Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Fortress Biotech (FBIO) over the last 12 years, with Q3 2025 value amounting to 38.63%.

  • Fortress Biotech's EBIT Margin rose 1124000.0% to 38.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 143.55%, marking a year-over-year increase of 261500.0%. This contributed to the annual value of 191.38% for FY2024, which is 229500.0% down from last year.
  • As of Q3 2025, Fortress Biotech's EBIT Margin stood at 38.63%, which was up 1124000.0% from 222.22% recorded in Q2 2025.
  • Fortress Biotech's 5-year EBIT Margin high stood at 38.63% for Q3 2025, and its period low was 473.63% during Q1 2023.
  • In the last 5 years, Fortress Biotech's EBIT Margin had a median value of 236.77% in 2021 and averaged 226.23%.
  • The largest annual percentage gain for Fortress Biotech's EBIT Margin in the last 5 years was 2673700bps (2023), contrasted with its biggest fall of -2760500bps (2023).
  • Fortress Biotech's EBIT Margin (Quarter) stood at 339.25% in 2021, then grew by 2bps to 333.05% in 2022, then skyrocketed by 70bps to 98.34% in 2023, then crashed by -60bps to 157.64% in 2024, then surged by 75bps to 38.63% in 2025.
  • Its last three reported values are 38.63% in Q3 2025, 222.22% for Q2 2025, and 169.85% during Q1 2025.